The oncology therapeutics developer, a spinoff from Spirogen, has increased the size of its initial public offering from almost $233m to nearly $268m.

ADC Therapeutics, a Switzerland-based cancer drug developer that was spun off by pharmaceutical firm AstraZeneca’s Spirogen subsidiary, closed its initial public offering at almost $268m yesterday. The company had initially floated on Friday, pricing more than 12.2 million shares at $19 each, above the IPO’s $16 to $18 range, and increased the size of the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.